title: Evaluation of levetiracetam effects on pilocarpine-induced seizures: cholinergic muscarinic system involvement.
abstract: Levetiracetam (LEV) is a new antiepileptic drug effective as adjunctive therapy for partial seizures. It displays a unique pharmacological profile against experimental models of seizures, including pilocarpine-induced seizures in rodents. Aiming to clarify if anticonvulsant activity of LEV occurs due to cholinergic alterations, adult male mice received LEV injections before cholinergic agonists' administration. Pretreatment with LEV (30-200 mg/kg, i.p.) increased the latencies of seizures, but decreased status epilepticus and death on the seizure model induced by pilocarpine, 400 mg/kg, s.c. (P400). LEV (LEV200, 200 mg/kg, i.p.) pretreatment also reduced the intensity of tremors induced by oxotremorine (0.5 mg/kg, i.p). [3H]-N-methylscopolamine-binding assays in mice hippocampus showed that LEV200 pretreatment reverts the downregulation on muscarinic acetylcholine receptors (mAChR), induced by P400 administration, bringing back these density values to control ones (0.9% NaCl, i.p.). However, subtype-specific-binding assays revealed that P400- and LEV-alone treatments result in M1 and M2 subtypes decrease, respectively. The agonist-like behavior of LEV on the inhibitory M2 mAChR subtype, observed in this work, could contribute to explain the reduction on oxotremorine-induced tremors and the delay on pilocarpine-induced seizures, by an increase in the attenuation of neuronal activity mediated by the M1 receptors.
authors.affiliation: Department of Physiology and Pharmacology, Laboratory of Neuropharmacology, School of Medicine, Federal University of Ceará, Rua Padre Frota, 189, Monte Castelo, Fortaleza, CEP 60325-160, Ceará, Brazil. alinealbuquer@hotmail.com
authors.forename: A A
authors.initials: AA
authors.lastname: Oliveira
authors.forename: C R A
authors.initials: CR
authors.lastname: Nogueira
authors.forename: V S
authors.initials: VS
authors.lastname: Nascimento
authors.forename: L M V
authors.initials: LM
authors.lastname: Aguiar
authors.forename: R M
authors.initials: RM
authors.lastname: Freitas
authors.forename: F C F
authors.initials: FC
authors.lastname: Sousa
authors.forename: G S B
authors.initials: GS
authors.lastname: Viana
authors.forename: M M F
authors.initials: MM
authors.lastname: Fonteles
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D003292:Convulsants / Q000633:toxicity; D004195:Disease Models, Animal; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D000077287:Levetiracetam; D008297:Male; D051379:Mice; D018721:Muscarinic Agonists / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D010862:Pilocarpine / Q000633:toxicity; D010889:Piracetam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000927:Anticonvulsants; D003292:Convulsants; D018721:Muscarinic Agonists; D011976:Receptors, Muscarinic; D010862:Pilocarpine; D000077287:Levetiracetam; D010095:Oxotremorine; D010889:Piracetam